Navigation Links
FDA approves IND on Lead Product M6G

CAMBRIDGE, England, 26th April 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, today announces that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of morphine-6-glucuronide (M6G), its novel drug for the treatment of post-operative pain. Earlier this year, CeNeS announced results of a Phase III study of M6G in Europe in over 500 patients with post-operative pain. The study demonstrated that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV). The opening trial under this IND will be a Phase I pharmacokinetic study in volunteers. This study is required by the FDA as is an additional pre-clinical toxicology analysis before progressing to Phase III trials. CeNeS is currently completing the protocol design of the first US Phase III trial. The filing of the IND enhances the package of data already available to potential US partners for review. Neil Clark, Chief Executive of CeNeS, said:

"The FDA's approval of our IND application for M6G is a major landmark in CeNeS' clinical development programme. North America is an attractive market for our drug candidate and M6G is clearly positioned to be a genuine alternative to standard morphine therapy."

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: '"/>




Page: 1 2

Related medicine technology :

1. FDA approves MyocondaR IND for MAP in Crohns Disease
2. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
3. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
4. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
5. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
6. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
7. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
8. PromegaExpress Expands Easy Access to Products with New Cabinet
9. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
10. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
11. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves IND Lead Product
(Date:9/3/2015)...  Four financial reasons to reduce pressure ulcers ... by Leaf Healthcare, Inc . According ... (AHRQ), pressure ulcers cost the US healthcare ... addition to direct treatment related costs, pressure ulcers ... impact hospital performance metrics. On top of the ...
(Date:9/3/2015)... Corporation (NASDAQ: OMER ) today announced that it ... and its subsidiary, Par Sterile Products, LLC, (collectively "Par") ... New Jersey and in the ... Delaware . The lawsuits were filed under the ... U.S. Patent Nos. 8,173,707, 8,586,633 and 9,066,856, which relate ...
(Date:9/3/2015)... , Sept. 3, 2015 Research and ... of the "Investigation Report on China,s Levothyroxine ... Thyroid hormones (TH) have the greatest ... younger ones. Without thyroid hormones mainly promote the ... organs, even the growth hormone (GH) of pipuitary ...
Breaking Medicine Technology:Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 3Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4Investigation Report on China's Levothyroxine Market, 2010-2019 2
(Date:9/3/2015)... CA (PRWEB) , ... September 03, 2015 , ... ... the real estate investment landscape by connecting accredited and institutional investors to real ... financing products designed to meet demand from both investors and sponsoring real ...
(Date:9/3/2015)... ... September 03, 2015 , ... Girl’s Night Out to benefit Core Compassion ... Farm, 6205 Kate Road in Monroe, North Carolina. The event food will ... social function, Kate Clyde’s offers off-premise catering and event services from casual to elegant. ...
(Date:9/3/2015)... WA (PRWEB) , ... September ... ... of Washington, a leading provider of comprehensive eating disorder treatment for adults ... announced today that Ileana Calinoiu, MD has joined the medical treatment team. ...
(Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology Nurse Advisor ... may help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated ... caused by HPV infections, which have a high rate of success in treatment and ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic ... virtual conference, “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” In this ... Scripts and Milliman, will discuss how plan sponsors are adopting bold, innovative strategies ...
Breaking Medicine News(10 mins):Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2
... ... ... ... ...
... - Researchers from The University of Texas M. D. ... to measure the severity of symptoms that can complicate ... chronic graft-versus-host disease (cGVHD), and was presented with supporting ... Meeting. cGVHD - a chronic disease that ...
... Radio ... This study appears in Plastic and Reconstructive Surgery, the offical medical journal of the American ... ... procedures in the world for excess fat removal - and while its relative safety and ...
... with type 1 disease from daily injections, expert predicts, , ... treatment with a hormone linked to weight loss seems to ... raising the prospect of a landmark new treatment for some ... as leptin, will work against type 1 diabetes. But if ...
... apt to enhance verbal skills, experts say, , MONDAY, ... their infants in front of supposedly brain-enhancing DVDs in ... be accomplishing nothing, new research shows. , What,s more, ... DVDs at an earlier age actually had lower levels ...
... ... ... ... ...
Cached Medicine News:Health News:Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference 2Health News:Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference 3Health News:Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference 4Health News:Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference 5Health News:M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms 2Health News:M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms 3Health News:New Study Tunes Into Latest Lipo Technique 2Health News:Hormone Outperforms Insulin in Diabetic Mice 2Health News:Watching Special Videos May Not Make Kids Brainier 2Health News:Watching Special Videos May Not Make Kids Brainier 3Health News:National Study Reports Staggering Spending Increases Among Seniors With Chronic Conditions Through Original Medicare - Special Needs Plan Program Offers Solution For Those In Texas 2Health News:National Study Reports Staggering Spending Increases Among Seniors With Chronic Conditions Through Original Medicare - Special Needs Plan Program Offers Solution For Those In Texas 3Health News:National Study Reports Staggering Spending Increases Among Seniors With Chronic Conditions Through Original Medicare - Special Needs Plan Program Offers Solution For Those In Texas 4
... technology is the first and ... patented digital sensor all ... sensor. Dolphin ONE™ sensors both ... in the sensor, resulting in ...
Immersion Oil, 21,000 cs...
Immersion Oil, 1,250 cs...
... standard - the ones to compare with, the ... led in the development and standardization of immersion ... record: , When the FDA set general purpose ... Diagnostics in the 1970's, Cargille Immersion Oils were ...
Medicine Products: